To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HR-positive, HER2-negative Breast Neoplasms
Interventions: DRUG: TQB3616 capsule|DRUG: Placebo|DRUG: Fulvestrant injection
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.